I am posting an email thread for the benefit of OWCP

New Post Public Reply Private Reply Replies (0) Message Board
Pussim
559

I am posting an email thread for the benefit of OWCP shareholders.

Since I have friends and family living there I am considering taking Yossi up on his offer and to see for myself and for the benefit of true OWCP longs wtf is going on there.

THis email and thread has been edited to preserve the privacy of the individual corresponding with Yossi. I spent 2 hours talking with this individual last night after he forwarded these emails to me.

Need to raise about 2k to fund the one week trip..hotel/airfare/expenses

We are thinking of setting up a gofundme page or something like that to fund the brief trip to Israel which would be 5-7 days.
I would take pictures and interview and ask questions, being a former broadcast journalist. )

I think it's time we get eyes on the ground there.
I have over 100k invested in the company.
Myself and close friends want some answers...

If any of shareholder wants to reach out to me in private..one of my emails is howyk@yahoo.com.


Original Message
From: Yossi Dagan
To: XXXXX XXXXX
Sent: Tuesday, January 15, 2019 3:02 PM
Subject: Re: OWC Pharmaceutical Research Corp.

Hi XXXXX,
I appreciate your email as always!
I will call you to discuss.
I can assure you that this company is not a scam, we are all working very hard to get things moving in the right direction, unfortunately it is not reflected in the share price.
I invite you to visit us in Israel, we can take you hand by hand to see and talk to the folks who are involved in the clinical trials if you want to see it from first hand and get comfort.
Thanks,
Yossi


On 15 Jan 2019, at 21:18, <xxxxxx@rogers.com> wrote:

Hello Yossi,

Not sure if you are aware or not but there is a lot of dissatisfaction with the Company and in particular with how it conducts its business and overall lack of concern with the sentiment of their investors. There are quite a few that are suggesting the company is a scam. The following is a facebook post by Alon Sinai on his facebook page.
https://www.facebook.com/alon.sinai.71?fref=p...riends_tab

Sure, on the surface it appears to be a positive post but on the other hand there are no shortage of skeptics that are probably thinking this is a last ditch effort to hopefully get the share price up again. There are 10 comments to the post. The two from Tomasz Torski are revealing: "Same product from 2 years ago?" and his latest "OWCP - scam alert!!!!" And Alon remains silent and does not refute the comment?

Another well informed investor posted the following comment:
https://www.prnewswire.com/news-releases/owc-...31521.html

In this pr the company announced the beginning of efficacy testing and then new er followed up on this pr. If there was in fact a test no harm no foul. But shortly after this pr the stock price doubled. And then soon ran to $3 and Jeffery Freidland illegally dumped his shares.

If there was no test, this pr is fraudulent and can link the company to Freidland pump and dump scheme. So there better damn well have been a test.it opens the company up to liability and a lawsuit if there never was one.

I do not think this has adequately been looked into. Based on the timelines alone.

The above post is very accurate. The elaborate plan to scam investors began long before you and Dr. Hirsch arrived on the scene, however a change in directors does not diminish the seriousness of the accusation, nor does it relieve the company of liability.

The 8-Ks filed below were before your time but they are nevertheless official filings. Whether all of the directors of the company were involved in the fraudulent pump and dump activity is questionably. But there is zero doubt that they were either complicit to what was going on, or they were being grossly negligent, stupid, or both!

12/29/2016 8-K
https://www.marketwatch.com/investing/Stock/O...amp;type=8
Quote:

On December 29, 2016, OWC Pharmaceutical Research Corp. (the “Registrant”), through its wholly-owned Israeli subsidiary, One World Cannabis Ltd. (‘OWC”), entered into a Research Agreement with Medical Research Infrastructure Development and Health Services Fund by Chaim Sheba Medical Center

Quote:

Pursuant to the Research Agreement, the Fund shall perform a Phase I, double blind, randomized, placebo-controlled, maximal dose study (the “Study”) to determine the safety, tolerability of topical cream containing MGC (“Medical Grade Cannabis” or the “Study Drug”) in healthy volunteers, employing the services of Dr. Aviv Barzilay, Director of the Department of Dermatology- Chaim Sheba Medical Center, Tel Hashomer, Israel, to lead the Study (the “Investigator”).

Quote:

2. PRE-CONDITION
It is a condition precedent to the validity of this Research Agreement that this Agreement shall come into effect only after approval is received from (i) the Helsinki Committee; and (ii) the Hospital’s Committee for Research Contracts with Commercial Companies. The performance of the Study shall commence only after both committees have approved the Study.

02/01/2017 8-K
https://www.marketwatch.com/investing/Stock/O...amp;type=8
Quote:

OWC Pharmaceutical Research Corp., OTCQB: OWCP (the “Registrant”), through its wholly-owned Israeli subsidiary, One World Cannabis Ltd. (“OWC Ltd”), has been conducting study on the efficacy its proprietary cannabinoid-based topical cream for the treatment of skin conditions generally and psoriasis specifically, which commenced in November, 2016 (the “Study”).

Quote:

On February 1, 2017, following the very encouraging results that have been achieved at the mid-point of the Study, the Registrant’s Board of Directors and the management and scientific personnel of OWC Ltd have determined to extend the size and scope of the Study for the purpose of, among other things, checking the biological markers that have been generated to date with respect to the treatment of psoriasis (proliferation/ inhibition and several interleukins). Despite extending its size and scope of the Study, the Registrant expects to compete the Study within the same projected time frame.

03/20/2017 8-K
https://www.marketwatch.com/investing/Stock/O...amp;type=8
Quote:

On March 20, 2017, OWC Pharmaceutical Research Corp. ("OWC"<clip_image001.gif> issued a press release announcing the promising preliminary results from the efficacy testing of its cannabinoid-based topical cream for treating psoriasis, reporting significant reduction of several inflammation markers specific to psoriasis. OWC announced that it anticipates that the topical cream will be market-ready during 2017 Q2 and, subject to regulatory approvals from applicable jurisdictions, the topical cream should be available for use by those who suffer from psoriasis in the near term.

04/4/2017 8-K
https://www.marketwatch.com/investing/Stock/O...amp;type=8
Quote:

OWC Pharmaceutical Research Corp. ("OWC"<clip_image001.gif> is reporting the issuance on April 5, 2017 of the attached press release, announcing that as a result of the promising conclusions reported in its Form 8-K filed on March 20, 2017, the Company has received expressions of scientific and medical interest, world-wide, for its cannabinoid-based topical cream for treating psoriasis.


Quote:

A wide and in-depth multi-layer clinical study on Psoriasis and psychological aspects is targeted to start next year, 2018, after collection of data from patients to carefully plan the targets of such a unique study that will show a combination of cannabinoids treatments for a specific disease.


Yossi,

I would appreciate it if you reply to my email asap. My patience is wearing very thin. I am friends with two individuals from the media. One is Ellen Roseman, a consumer advocate for the Toronto Star, and the other is Brian Milner of The Globe and Mail, a senior economics writer, columnist, and writer. As you can appreciate I have a treasure trove of documents related to the company that they could find useful for their work. I am not necessarily referring to emails with Alon Sinai, and certainly not with you. Specifically, I am referring to communication with Amir Uziel, Jeff Smurlick, Jeffrey Friedland, and last but not least Richard Rubin, the disbarred lawyer referred to me by the company. A lot of communication had to do with the release of the above 8-Ks.

This should not in any way be taken as a threat, because if the company is indeed legit, then I don't want to compound the situation by making things worse.

If you prefer to call me on my cell xxx-xxx-xxxx, that's fine with me.

Regards,

XXXX

Original Message
From: Yossi Dagan
To: XXXXX
Sent: Monday, December 31, 2018 11:44 PM
Subject: Read: Fw: OWC Pharmaceutical Research Corp. - Recent 8-K

Your message

To: Yossi Dagan
Subject: Fw: OWC Pharmaceutical Research Corp. - Recent 8-K
Sent: Monday, December 31, 2018 11:09:22 PM (UTC+02:00) Jerusalem

was read on Tuesday, January 1, 2019 6:44:15 AM (UTC+02:00) Jerusalem.

OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links

OWCP Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Updated Category News Views 263

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 321

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 254

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
Breakthrough T1D Pushes Global T1D Awareness Forward

Updated Category News Views 192

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 327

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 303

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 127

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
Beko Pushes for Policy Synergy Amidst Carbon Shakeup

Updated Category News Views 190

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

Continue Reading
HiTHIUM Joins Cambridge to Boost Global Energy Storage

Updated Category News Views 421

HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 344

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading
News Articles